Preclinical study reveals new cream may prevent or slow growth of some common skin cancers

(Press-News.org) PHILADELPHIA – A topical cream activated the skin’s immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published today in the Journal of Clinical Investigation. Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream works by blocking LSD1, an enzyme that suppresses immune‑activating pathways in the skin.

“What’s striking is that a simple topical cream can use the skin’s own machinery to recruit and activate immune cells that attack tumors,” said senior author Brian C. Capell, MD, PhD, an assistant professor of Dermatology at Penn. “We are carrying out some more studies to refine the formulation this coming year, and we hope to begin a phase 1 clinical trial in the next 1-2 years. Ideally, this cream could be used directly on cancerous and precancerous spots.”

A common cancer with few options for lesions that spread

cSCC is one of the most common cancers, with about a million  Americans diagnosed each year, and incidence continues to rise with an aging population  and people spending more time in the sun. While most cases are treatable with surgery, up to five percent of tumors metastasize, leading to thousands of deaths annually in the United States. Many older or immunocompromised patients develop dozens of precancerous lesions across large areas of skin, making repeated procedures burdensome and, at times, unfeasible.

Current options for widespread lesions, like chemotherapy, are not targeted to the cancer, and other targeted treatments can be painful. Surgery remains effective but is invasive and carries risks such as infection and scarring. A topical approach that activates anti‑tumor immune responses locally could reduce the need for repeated procedures and help prevent progression to invasive cancer.

A new way to “wake up” the skin’s immune response

In the study, Penn researchers formulated a low‑dose topical inhibitor of LSD1, an enzyme that normally acts as a “brake” on certain immune‑activating pathways in epidermal cells. By “lifting the brake,” the cream prompted skin cells to signal for immune help.Those cells played a key role in slowing down tumor growth.

In the study, blocking retinoic acid signaling, a naturally-occurring and important type of basic cellular signaling that tells cells how to grow and develop, reversed many of the skin level changes induced by the cream. In addition, destroying CD4⁺ T cells (a type of immune cell) eliminated its tumor suppression. The findings suggest the therapy works by priming communication between skin cells and the immune system to enable targeted anti‑tumor responses.

While treating skin cancer would be a huge benefit from this treatment, preventing cancer from forming in the first place could have an even larger impact. An estimated 58 million Americans live with skin precancers or early squamous cell carcinomas each year, and a topical treatment could reduce the need for repeated surgeries and lower the number of lesions that progress to invasive cancer. The researchers are also exploring whether taking LSD1 inhibitors orally or in an injection could enhance the efficacy of immune checkpoint cancer therapies. These types of therapies are currently effective in only a subset of patients with advanced cSCC.

Other Penn authors of this study include first author Nina Kuprasertkul, as well as Alyssa F. Moore, Carina A. D’souza, Julia Chini, Eun-Kyung Ko, Sijia Huang, Shuo Zhang, Ashley S. Anderson, Shaun Egolf, Laura V. Pinheiro, Alison Jaccard, Claudia T. Magahis, Lydia Bao, Yann Aubert, Cyria Olingou, Stephen M. Prouty, Donna Brennan-Crispi, David A. Hill, John T. Seykora, and Kathryn E. Wellen.

This research was supported by the National Institutes of Health (K08AR070289, P30-AR069589, R01AR077615, R01CA262055, R01HL162715, T32GM007170, T32AR007465), the Damon Runyon Cancer Research Foundation, the Dermatology Foundation, and the Skin Cancer Foundation.

END